A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia A
This intra-patient comparison demonstrates switching from SHL FVIII to rFVIIIFc prophylaxis reduces frequency of bleeds, injection frequency, and factor consumption, complementing previously reported data from A-SURE.<b>Trial registration:</b>ClinicalTrials.gov identifier: NCT02976753.
Authors
- Ingrid Pabinger (ORCID: https://orcid.org/0000-0002-7677-9896)
- Anna‐Elina Lehtinen
- Stefan Lethagen (ORCID: https://orcid.org/0000-0002-8436-1780)
- C. R. M. Hay (ORCID: https://orcid.org/0000-0002-0162-6828)
- Eveline Nüesch
- Flora Peyvandi (ORCID: https://orcid.org/0000-0001-7423-9864)
- Johannes Oldenburg (ORCID: https://orcid.org/0000-0002-1585-4100)
- Håkan Malmström (ORCID: https://orcid.org/0000-0003-3315-5618)
- Eva Bednar
Institutions
- Statistics Sweden (SE)
- University of Helsinki (FI)
- University of Bonn (DE)
- University of Milan (IT)
- University Hospital Bonn (DE)
- Helsinki University Hospital (FI)
- Manchester Royal Infirmary (GB)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Thrombosis Research Institute (GB)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Hematology
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1080/16078454.2025.2513186
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Swedish Orphan Biovitrum